Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms

Abstract

Purpose This study aimed to investigate the characteristics of colonic neuroendocrine neoplasms (NENs) and to validate the prognostic value of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems. Methods A total of 167 and 1248 patients with colonic NENs from 12 medical centers across China and from the Surveillance, Epidemiology, and End Results (SEER) cancer registry in the United States, respectively, were reviewed. Patients were staged according to the ENETS and AJCC 8th staging systems. Results Clinicopathological features of colonic NENs in the Chinese cohort and SEER cohort were significantly distinct. In both the Chinese cohort and the SEER cohort, colonic neuroendocrine carcinoma (NEC) and mixed adeno‐neuroendocrine carcinoma (MANEC) were more frequent in the midgut than in the hindgut. Tumors originating from the midgut tended to be larger and at a more advanced stage than those from the hindgut. The AJCC 8th staging system and the ENETS system appeared to have similar prognostic ability for colonic NEC/MANEC. Conclusions Our study revealed that tumors originating from the midgut and the hindgut shared different clinicopathological features. The AJCC 8th staging system and the ENETS system appeared to have similar prognostic ability for colonic NEC/MANEC.

WITHDRAWN: Survival Nomograms for Patients with Pancreatic Neuroendocrine Tumors: A Population-based Study

“…Surgical treatment is always recommended for patients with PNETs with or without distant metastasis. Similar to pancreatic ductal adenocarcinoma [17], patients with tumors located in the tail or body of the pancreas have a more favorable outcome. Although several studies have demonstrated that nomograms could be ideal statistical prediction models for PNETs [18,19,20], our updated nomograms were established with more detailed clinical information after excluding indeterminacy parameters from the SEER database.…”

WITHDRAWN: Survival Nomograms for Patients with Pancreatic Neuroendocrine Tumors: A Population-based Study

“…Surgery treatment always was recommend for PNETs patients with or without distant metastasis. As similar to pancreatic ductal adenocarcinoma [17], the patient whose tumor located in tail or body of pancreas has more favorable outcome.…”

Seronegative fibrosing cholestatic hepatitis С after liver retransplantation for unresectable neuroendocrine tumor liver metastases

“…Однако авторы указывают на необходимость тщательного отбора пациентов с учетом определенных критериев. Все предложенные критерии (Mayo Clinic, UWO, ENETS) подразумевают обязательное удаление первичного очага (индекс Ki-67 менее 2%), отсутствие внепеченоч-ных метастазов и стабилизацию процесса на фоне проводимой терапии в течение не менее 6-12 мес [4]. Таким образом, ТП можно рассматривать как единственный радикальный метод лечения этой категории пациентов [3,4,9].…”

“…Лечение больных с нерезектабельными метастазами нейроэндокринного рака является серьезным вызовом онкологам и хирургам во всем мире [1,2]. Низкий потенциал злокачественности некоторых нейроэндокринных опухолей позволяет рассматривать трансплантацию печени (ТП) как единственный радикальный метод лечения данной категории больных [3,4]. В ведущих клиниках США и ЕС разработаны и успешно приме-няются критерии ТП больным с нерезектабельными метастазами нейроэндокринного рака [5,6].…”